Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -1.02 | -0.34 | -0.05 |
| FCF Yield | 0.38% | 0.71% | -1.28% | 1.37% |
| EV / EBITDA | 25.08 | 102.17 | -48.69 | -66.28 |
| Quality | ||||
| ROIC | 3.15% | 0.41% | -3.61% | -0.84% |
| Gross Margin | 78.50% | 93.90% | 89.30% | 93.37% |
| Cash Conversion Ratio | 0.11 | 3.26 | 0.60 | -0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.48% | 6.20% | 0.21% | -1.13% |
| Free Cash Flow Growth | -15.64% | 160.56% | -192.69% | 24.54% |
| Safety | ||||
| Net Debt / EBITDA | 2.09 | -2.96 | 1.07 | 2.20 |
| Interest Coverage | 0.00 | 7.32 | -41.77 | -10.91 |
| Efficiency | ||||
| Inventory Turnover | 2.09 | 0.23 | 0.41 | 0.20 |
| Cash Conversion Cycle | -12.24 | 212.87 | 204.71 | 370.97 |